Atherosclerosis
Conditions
Brief summary
Clopidogrel is a antiplatelet agent and is effective at reducing intimal hyperplasia in animal models of thrombosis.Several large clinical trials have demonstrated that clopidogrel with aspirin can reduce ischemic events and mortality in patients with atherosclerotic disease,therefore the combination of two antiplatelets might be useful to prevent patients received coronary artery bypass graft surgery from Saphenous vein graft disease. the aim of this study is to estimate the safety and efficacy of clopidogrel and aspirin therapy versus aspirin alone in patients after CABG.
Interventions
clopidogrel 75mg daily and aspirin 100mg daily
DRUGaspirin
aspirin 100mg daily
Sponsors
China National Center for Cardiovascular Diseases
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients undergoing primary multi-vessel CABG with at least two saphenous vein grafts, with or without the use of cardiopulmonary bypass.
Exclusion criteria
* Emergency surgery * Valve surgery * Redo CABG * Left ventricle ejection fraction \< 30% * Preoperative use of clopidogrel (with the exception of the current admission) * Preoperative use of warfarin * Allergy to aspirin or clopidogrel * History of cerebrovascular accident * History of severe liver disease * Morbid obesity * Current malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vein graft patency examined by CT scan | three months after surgery |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of major adverse coronary events Incidence of major bleeding events | two years following surgery |
Countries
China
Outcome results
None listed